Bafna Pharmaceuticals share news and announcements
NSE: BAFNAPHBSE: 532989Pharmaceuticals & BiotechnologySmall Cap
Last close ₹442.95down ₹9.00 (1.99%)BSE ₹449.85
Share price at the NSE close on 23 Oct 2026. Previous close ₹451.95.
52-week range of traded prices to 23 Oct 2026
₹94.77Low, 16 Mar 2026₹479.95High, 21 Oct 2026
- Delivery only: shares bought must be paid for in full, with no selling on the same day.
- Market capMarket capitalisation. Share price times the number of shares: what the whole company is worth at the day's price. The rank is by average market value over the six months to Jun 2026, among listed companies.
- ₹1,048 Cr2,105th largest listed
- P/EPrice to earnings, trailing. Market cap divided by the profit of the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, after the share of the other owners of its subsidiaries: what investors pay for each rupee of a year's profit. The filing of 11 Aug 2026
- 134.6
- P/BPrice to book. Market cap divided by the net worth that belongs to the company's own shareholders, its assets less everything it owes and less the other owners' share of its subsidiaries, on its latest balance sheet. The filing of 29 May 2026
- 10.9
- Dividend yieldDividend yield. Dividends paid per share in the twelve months to the day, as a percentage of the day's share price.
- Nonein the last 12 months
- ROEReturn on equity. Profit over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly) that belongs to the company's own shareholders, as a percentage of their net worth, the money they have in the business. Net worth is the average of the latest balance sheet and the one a year before it. The filing of 11 Aug 2026
- 8.6%
- ROCEReturn on capital employed. Operating profit after depreciation (revenue less operating expenses and depreciation, without other income and one-off items) as a percentage of all the money the business runs on: the whole group's net worth, the other owners of its subsidiaries included, plus borrowings. Lease liabilities are not counted: the results filings do not state them. The profit is over the last twelve months (the latest four quarters, or two half years for a company that reports half-yearly); net worth and borrowings are on the latest balance sheet. The filing of 11 Aug 2026
- 4.0%
- Debt to equityDebt to equity. Borrowings divided by the whole group's net worth, the other owners of its subsidiaries included: rupees borrowed for each rupee of equity in the business. Lease liabilities are not counted: the results filings do not state them. From the balance sheet at the end of Mar 2026. The filing of 29 May 2026
- 0.39
- Volume, NSEVolume. Shares traded on the last trading day.
- 1,422
Bafna Pharmaceuticals results
106 filed, newest first. Page 2 of 3.
Feb 2017
Nov 2016
Sep 2016
Aug 2016
May 2016
Feb 2016
Nov 2015
Aug 2015
May 2015
Feb 2015
Nov 2014
Sep 2014
Aug 2014
Jun 2014
May 2014
Feb 2014
Nov 2013
Oct 2013
Aug 2013
May 2013
Apr 2013
27 Apr · Results
Company will publish its Audited Annual Accounts for the financial year ending March 31, 2013 on or before May 30, 2013, hence will not ....
Feb 2013
Dec 2012
Nov 2012
Aug 2012
May 2012
Apr 2012
27 Apr · Results
Company opted to submit audited financial results for the entire financial year within sixty days of end of the financial year ending ....
Feb 2012
Nov 2011
Aug 2011
May 2011
11 May · Results
Company opts to submit audited financial results for the entire financial year within sixty days of end of the financial year ending March 31, 2011.